Laboratory reproducibility of biochemical markers of bone turnover in clinical practice

Springer Science and Business Media LLC - Tập 21 - Trang 439-445 - 2009
A. L. Schafer1,2, E. Vittinghoff3, R. Ramachandran4, N. Mahmoudi5, D. C. Bauer1,6
1Department of Medicine, University of California, San Francisco, USA
2San Francisco, USA
3Department of Epidemiology and Biostatistics, University of California, San Francisco, USA
4Department of Pathology, University of California, San Francisco, USA
5Department of Medicine, Kaiser Permanente, Oakland, USA
6Department of Epidemiology and Biostatistics, University of California San Francisco, USA

Tóm tắt

To determine the laboratory reproducibility of urine N-telopeptide and serum bone-specific alkaline phosphatase measurements, we sent identical specimens to six US commercial labs over an 8-month period. Longitudinal and within-run laboratory reproducibility varied substantially. Efforts to improve the reproducibility of these tests are needed. We assessed the laboratory reproducibility of urine N-telopeptide (NTX) and serum bone-specific alkaline phosphatase (BAP). Serum and urine were collected from five postmenopausal women, pooled, divided into identical aliquots, and frozen. To evaluate longitudinal reproducibility, identical specimens were sent to six US commercial labs on five dates over an 8-month period. To evaluate within-run reproducibility, on the fifth date, each lab was sent five identical specimens. Labs were unaware of the investigation. Longitudinal coefficients of variation (CVs) ranged from 5.4% to 37.6% for NTX and from 3.1% to 23.6% for BAP. Within-run CVs ranged from 1.5% to 17.2% for NTX. Compared to the Osteomark NTX assay, the Vitros ECi NTX assay had significantly higher longitudinal reproducibility (mean CV 7.2% vs. 30.3%, p < 0.0005) and within-run reproducibility (mean CV 3.5% vs. 12.7%, p < 0.0005). Reproducibility of urine NTX and serum BAP varies substantially across US labs.

Tài liệu tham khảo

Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD (1994) Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693–1700 Ravn P, Hosking D, Thompson D, Cizza G, Wasnich RD, McClung M, Yates AJ, Bjarnason NH, Christiansen C (1999) Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 84:2363–2368 Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051–1056 Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, Collette J (2004) Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34:344–351 Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD, Fracture Intervention Trial Study Group (2004) Changes in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19:1250–1258 Fraser WD, Anderson M, Chesters C, Durham B, Ahmad AM, Chattington P, Vora J, Squire CR, Diver MJ (2001) Circadian rhythm studies of serum bone resorption markers: implications for optimal sample timing and clinical utility. In: Eastell R, Baumann M, Hoyle NR, Wieczorek L (eds) Bone markers: biochemical and clinical perspectives. Martin Dunitz, London, pp 107–118 Seibel MJ, Lang M, Geilenkeuser WJ (2001) Interlaboratory variation of biochemical markers of bone turnover. Clin Chem 47:1443–1450 Vangel MG (1996) Confidence intervals for a normal coefficient of variation. Am Stat 50:21–26 Feltz CJ, Miller GE (1996) An asymptotic test for the equality of coefficients of variation from k populations. Stat Med 15:647–658 Seibel MJ, Woitge HW, Farahmand I, Oberwittler H, Ziegler R (1998) Automated and manual assays for urinary crosslinks of collagen: which assay to use? Exp Clin Endocrinol Diabetes 106:143–148 Vesper HW, Smith SJ, Audain C, Myers GL (2001) Comparison study of urinary pyridinoline and deoxypyridinoline measurements in 13 US laboratories. Clin Chem 47:2029–2031 Binkley N, Krueger D, Cowgill CS, Plum L, Lake E, Hansen KE, DeLuca HF, Drezner MK (2004) Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. J Clin Endocrinol Metab 89:3152–3157 Binkley N, Krueger D, Gemar D, Drezner MK (2008) Correlation among 25-hydroxy-vitamin D assays. J Clin Endocrinol Metab 93:1804–1808 Hollis BW (2004) The determination of circulating 25-hydroxyvitamin D: no easy task. J Clin Endocrinol Metab 89:3149–3151 Tortajada-Genaro LA, Cózar MP, Frigols JL, de Avila CR (2007) Comparison of immunoradiometric assays for determination of thyroglobulin: a validation study. J Clin Lab Anal 21:147–153 Holvoet P, Macy E, Landeloos M, Jones D, Jenny NS, Van de Werf F, Tracy RP (2006) Analytical performance and diagnostic accuracy of immunometric assays for the measurement of circulating oxidized LDL. Clin Chem 52:760–764 Lee JS, Ettinger B, Stanczyk FZ, Vittinghoff E, Hanes V, Cauley JA, Chandler W, Settlage J, Beattie MS, Folkerd E, Dowsett M, Grady D, Cummings SR (2006) Comparison of methods to measure low serum estradiol levels in postmenopausal women. J Clin Endocrinol Metab 91:3791–3797